Corient Private Wealth
BTTX

Corient Private Wealth’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Corient Private Wealth’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-29,180
Closed -$5.69K – 2391
2023
Q4 		$5.69K Buy
+29,180
New +$6.34K ﹤0.01% 2243

Other funds holding BTTX

CIAS
Capital Investment Advisory Services Raleigh, North Carolina $1.62B AUM 27.01% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Corient Private Wealth's BTTX Position: Q1 2024 in Review

Corient Private Wealth sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q1 2024, closing a stake of 29,180 shares — an estimated $5.69K sold.

Corient Private Wealth first reported a position in BTTX in Q4 2023 and held it in 1 quarter. The position peaked at $5.69K in Q4 2023. 3 funds tracked by Wall St. Rank hold BTTX as of Q1 2024.

  • Corient Private Wealth reported no remaining Better Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Corient Private Wealth sold 29,180 Better Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $5.69K.
  • Corient Private Wealth first reported a position in Better Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Corient Private Wealth's Better Therapeutics, Inc. Common Stock position peaked at $5.69K in Q4 2023.
  • 3 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Corient Private Wealth's 13F filing for Q1 2024, filed 9 May 2024.